ALGO Falls 19.05% Over the Past Month After Allegro Secures $35 Million Veterinary Licensing Agreement

As of November 25, 2025,

dropped by 0.14% over the last day to $0.1436. This reflects a 0.35% decrease for the week, a 19.05% loss over the past month, and a 57.07% decline since the start of the year. These price changes coincided with a significant business announcement from Allegro, the biotech firm responsible for ALGO.

Allegro Secures $35 Million Licensing Deal with American Regent for Synoglide™ in Equine Osteoarthritis

Allegro NV has entered into an exclusive licensing arrangement with American Regent, a Daiichi Sankyo subsidiary, granting them global veterinary commercialization rights for Synoglide™. The agreement includes an upfront payment to Allegro, with potential milestone and royalty payments that could reach $35 million. Allegro will maintain the rights for human use of the technology, consistent with its focus on developing treatments for human degenerative joint conditions.

Synoglide™, an injectable hydrogel developed using Allegro’s proprietary INTRICATE nanotechnology platform, is intended for managing osteoarthritis in horses. Lucas Decuypere, Allegro’s CEO, highlighted that the collaboration with American Regent, a prominent animal health company, affirms the promise of their technology.

Product Launch Set for Early 2026, Marketing to Begin in December

American Regent aims to unveil Synoglide™ at the American Association of Equine Practitioners (AAEP) conference in December 2025, a major event for veterinary professionals. The product is anticipated to become available in the U.S. in early 2026. Paul Diolosa, American Regent’s CEO, described Synoglide™ as an innovative approach to a challenging and chronic animal health issue, reinforcing the company’s dedication to advancing veterinary medicine.

Under the agreement, Allegro will also handle manufacturing, producing Synoglide™ in its advanced cleanroom facilities. While this partnership is expected to strengthen Allegro’s financial outlook in the long run, the immediate effect on ALGO’s stock price remains uncertain amid its ongoing decline.

Emphasis on Human Application Potential

The licensing arrangement underscores Synoglide™’s potential for use in human medicine, as horses are a recognized model for studying human joint diseases. Allegro’s ability to capitalize on this cross-species relevance may be crucial for its future human osteoarthritis programs. However, the company has yet to announce specific timelines or investment details for human clinical studies under this agreement.

Although the $35 million agreement marks a major achievement for Allegro, the ultimate outcome will hinge on Synoglide™’s acceptance in veterinary practice, regulatory approvals, and ongoing innovation in nanotechnology-based treatments. For now, investor sentiment remains cautious, as reflected by ALGO’s persistent price weakness.